Active Pharmaceutical Ingredients Market - The Position of the Major Leaders After FIVE Years

1. MarketsandMarkets Presents Active Pharmaceutical Ingredients Market: The Position of the Major Leaders After FIVE Years https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

2. The report "Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW). Browse: 369 market data tables 46 figures 312 pages And in-depth TOC on ?Active Pharmaceutical Ingredients/API Market? Download The PDF Brochure@ https://www.marketsandmarkets.com/pdfdownload.asp?id=263 The global active pharmaceutical ingredients market is expected to reach USD 213.97 Billion by 2021 from USD 157.95 Billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

3. Market Stakeholders: • Medical image management software providers • Diagnostic imaging equipment vendors/service providers • Standalone image management software/workstation providers • Healthcare IT service providers • Research and consulting firms • Diagnostic imaging centers • Hospitals • Venture capitalists • Government agencies • Market research and consulting firms https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

4. Market Drivers: • Increasing Incidence of Chronic Diseases • Rising Prevalence of Cancer • Technological Advancements in API Manufacturing • Growing Importance of Generics • Rapidly Increasing Geriatric Population • Increase in Abbreviated New Drug Applications (ANDA) • Increasing Uptake of Biopharmaceuticals Talk to Our Research Experts@ https://www.marketsandmarkets.com/speaktoanalyst.asp?id=263 Restraints: • Stringent Regulatory Requirements • Unfavorable Drug Price Control Policies Across Various Countries https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

5. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

6. On the basis of type, the active pharmaceutical ingredients market is segmented into innovative and generic APIs. The innovative APIs segment is estimated to command the largest share in 2016. Some of the major factors contributing to its large share include growing demand for innovative therapeutics for treatment of dreadful diseases, especially cancer, the increase in the number of FDA approvals for new molecular entities and the higher prices of innovative APIs (as compared to generics). On the basis of type of manufacturer, the active pharmaceutical ingredients market is segmented into captive and merchant API manufacturers. The APIs market, on the basis of type of synthesis, is segmented into synthetic and biotech APIs. Synthetic APIs is estimated to dominate this market in 2016. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

7. The large share of this segment can be attributed to the emergence of new synthetic molecules in the market, increasing number of new product approvals, less complex manufacturing and approval processes as compared to biologics and technological advancements in the method of synthesis. However, the biotech APIs market is expected to grow at a substantially higher rate during the forecast period owing to advances in biotechnology, growing demand for biopharmaceuticals due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies. Based on product, the biotech active pharmaceutical ingredients market is segmented into monoclonal antibodies, hormones, vaccines, cytokines, fusion proteins, therapeutic enzymes, and blood factors. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

8. In 2015, the monoclonal antibodies segment account accounted for the largest share of the global biotech active pharmaceutical ingredients market. Growing incidence of cancer, increasing investments in R&D, technological advances in genetic sequencing and target gene selection, and increasing application of mAbs in oncology reduced side effects as compared to chemotherapy are some of the major factors responsible for the large share of monoclonal antibodies in this market. Based on geography, the global active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2016. This large share can be attributed to various factors including increasing incidence of chronic diseases, increasing focus of the government on the growing adoption of generic drugs, rising demand for biologics and specialty drugs, and technological advances in API manufacturing. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

9. Prominent Players: • Pfizer, Inc. (U.S.) • Novartis International AG (Switzerland) • Sanofi (France) • Boehringer Ingelheim (Germany) • Bristol-Myers Squibb (U.S.) • Teva Pharmaceutical Industries Ltd. (Israel) • Eli Lilly and Company (U.S.) • GlaxoSmithKline plc (U.K.) • Merck & Co., Inc. (U.S.) • AbbVie Inc. (U.S.). https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

10. The Active pharmaceutical ingredients market is highly competitive and fragmented with many big and small players as well as contract manufacturing organizations. Pfizer, Inc., a leading player in the APIs market. Pfizer’s leading position in the market can be attributed to its exhaustive product portfolio spread across its business segments includng Global Innovative Pharmaceuticals (GIP); Global Established Pharmaceuticals (GEP); and Global Vaccines, Oncology. As part of its growth strategy, the company focuses on adopting both organic and inorganic growth strategies such as agreements, partnerships, collaborations, approvals, and acquisitions. In accordance with this, in June 2016, Pfizer acquired Anacor Pharmaceuticals, Inc. (U.S.), a leading biopharmaceutical company developing small molecule therapeutics. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

11. Novartis International AG (Switzerland), is another leading player in this market. The co?pa?y’s strengths lie in its strong brand recognition and robust product portfolio. the company invests a significant amount of its revenue in R&D activities. In 2015, the company invested 18.0% of its total revenue (USD 8.9 billion) on R&D. This significant investment in R&D enables the company to launch innovative and technologically advanced products in the market. Novartis also focuses on inorganic growth strategies to sustain its foothold in the market. For instance, in June 2016, Novartis entered into a licensing and collaboration agreement with Xencor (U.S.), a biopharmaceutical company that develops engineered monoclonal antibodies. The purpose of this agreement was to develop bispecific antibodies for treating cancer. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

12. The key strategies followed by most companies in the Active pharmaceutical ingredients market are agreements, collaborations, partnerships, joint ventures, and alliances; regulatory approvals, mergers and acquisitions; expansions and investments. Among all growth strategies adopted by market players, agreements, collaborations, partnerships, joint ventures, and alliances accounted for the largest share of the overall growth strategies mapped from 2013 to 2016. Some leading players adopting these strategies include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and Merck & Co., Inc. (U.S.). https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

13. About MarketsandMarkets™ Marketsa?dMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide co?pa?ies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach Marketsa?dMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at Marketsa?dMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. Marketsa?dMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. Marketsa?dMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. Marketsa?dMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

14. Contact Us Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 Email: sales@marketsandmarkets.com MarketsandMarkets Blog http://www.marketsandmarkets.com http://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets